CD30在EBV阳性弥漫性大B细胞淋巴瘤中的表达及其预后意义  

Expression and prognostic significance of CD30 protein in EBV-positive diffuse large B-cell lymphoma

作　　者：刘谦[1] 刘勇[1] 戴艳枝[1] 袁晟[1] 喻友爱 刘秀娇 徐芳华 LIU Qian;LIU Yong;DAI Yanzhi;YUAN Sheng;YU Youai;LIU Xiujiao;XU Fanghua(Department of Pathology,Jiangxi Provincial People's Hospital,Jiangxi Nanchang 330006,China;Department of Pathology,Pingxiang Hospital Affiliated to Southern Medical University,Jiangxi Pingxiang 337000,China)

机构地区：[1]江西省人民医院病理科,江西南昌330006 [2]南方医科大学附属萍乡医院病理科,江西萍乡337000

出　　处：《现代肿瘤医学》2022年第23期4299-4303,共5页Journal of Modern Oncology

基　　金：江西省卫生健康委员会普通科技计划(编号:20195029)。

摘　　要：目的:探讨CD30在EBV阳性弥漫性大B细胞淋巴瘤(EBV-positive diffuse large B-cell lymphoma,EBV+DLBCL)中的表达及预后意义。方法:回顾性分析322例DLBCL中EBV+DLBCL与EBV-DLBCL病例临床病理参数之间的关系,以及CD30在EBV+DLBCL中的表达及预后意义。结果:CD30在EBV+DLBCL病例中的表达多于EBV-DLBCL病例(P=0.002);EBV-DLBCL中双表达的病例多于EBV+DLBCL(P=0.044);在63例EBV+DLBCL中,CD30阳性表达多见于B症状患者(P=0.015);另外有2例EBV+DLBCL病例出现BCL6基因重排。随访139例患者中,共表达CD30和EBER的患者预后较差(P=0.002);在EBV+DLBCL中,CD30阳性提示预后更差(P=0.028)。结论:CD30在EBV+DLBCL病例中具有较高的表达率,且与患者不良预后相关,进一步为靶向药物的使用提供理论依据。Objective:To investigate expression and prognostic significance of CD30 protein in EBV-positive diffuse large B-cell lymphoma(EBV+DLBCL).Methods:The relationship of clinicopathological data in 322 DLBCL(EBV+DLBCL and EBV-DLBCL)cases were analyzed restrospectively.Meanwhile,we assessed the expression and prognostic significance of CD30 in EBV+DLBCL.Results:The expression of CD30 in EBV+DLBCL was higher than that in EBV-DLBCL(P=0.002).MYC/BCL2 double expression were commonly been seen in EBV-DLBCL compared with EBV+DLBCL(P=0.044).Strong immunoreactivity of CD30 was associated with B-symptoms in 63 EBV+DLBCL(P=0.015).Besides,we found BCL6 gene rearrangement in 2 EBV+DLBCL.Of the 139 patients were followed up,CD30 expression combined with EBV conferred an inferior outcome(P=0.002).The positive expression of CD30 indicated a worse prognosis in EBV+DLBCL(P=0.028).Conclusion:CD30 expression level in EBV+DLBCL is significantly high,which is associated with poor prognosis,providing a theory basis for the use of targeted drugs.

关 键 词：EBV阳性弥漫性大B细胞淋巴瘤 CD30 预后意义 

分 类 号：R733.4[医药卫生—肿瘤]